The cost of headache disorders in Europe: the Eurolight project

Linde, Mattias; Gustavsson, Anders; Stovner, Lars Jacob; Steiner, Timothy J.; Barré, Jessica; Katsarava, Zaza; Laínez, José Miguel; Lampl, Christian; Lantéri-Minet, Michel; Rastenytė, Daiva; Torre, Elena Ruiz de la; Tassorelli, Cristina; Andrée, Colette

doi:10.1111/j.1468-1331.2011.03612.x

Cited by 605 publications

(581 citation statements)

References 26 publications

Supporting

Mentioning

523

Contrasting

Unclassified

Order By: Relevance

“…In Europe, this cost is estimated at €1222 [39,40]. Migraine burden is bound to increase by more than 10% DALYs within the next decade [41].…”

Section: Therapeutic Aspectsmentioning

confidence: 99%

Migraine in Women: What Specificities? A Review

Boubacar¹,

Seck²,

Assadeck³

et al. 2017

J Women's Health Care

View full text Add to dashboard Cite

The migraine is a chronic neurological disease that affects 10 to 12% of the population, with a clear preponderance females and this from puberty. The women report a longer attack duration. Presence and severity of associated symptoms, such as photophobia, phonophobia, nausea, vomiting, and cutaneous allodynia are more prevalent in women. Some clinical forms are well described as catamenial migraine. Several comorbidities have been described in migraine women. Among these diseases associated with migraine: vascular diseases, asthma, allergies, epilepsy, restless legs syndrome, and various chronic pain syndromes and psychiatric disorders. Treatment of migraine in women raises the difficulty of managing seizures and during pregnancy and the period of menstruation. The therapeutic difference mainly concerns menstrual migraine. In women with migraine, it is therefore recommended to be particularly attentive to comorbidities, the presence of which significantly increases the risk of arterial vascular events. Migraine is very common with a particular impact on the quality of life of women. These various specificities and their evolution over time must lead to continuous training of general practitioners, other specialists in women's health including gynecologists in order to reduce the morbidity of the disease by better prevention of crises through the harmonization of research by scientific societies from different continents.

show abstract

“…In Europe, this cost is estimated at €1222 [39,40]. Migraine burden is bound to increase by more than 10% DALYs within the next decade [41].…”

Section: Therapeutic Aspectsmentioning

confidence: 99%

Migraine in Women: What Specificities? A Review

Boubacar¹,

Seck²,

Assadeck³

et al. 2017

J Women's Health Care

View full text Add to dashboard Cite

show abstract

“…Jellemzően a 40-50 év közötti korosztályban a leggyakoribb [10]. Részben ezzel, részben gyakoriságával magyaráz-ható, hogy az FTTF társadalmi szinten a legköltségesebb neurológiai betegségek közé tartozik [11]. A költségek túlnyomó része úgynevezett indirekt költség, amely a gyakori fejfájások miatt kieső vagy csökkent produktivitású munkából adódik.…”

unclassified

Fájdalomcsillapító-túlhasználathoz társuló fejfájás

et al. 2015

View full text Add to dashboard Cite

A fájdalomcsillapító-túlhasználathoz társuló fejfájás a lakosság 1-2%-át érinti. Bármely fájdalomcsillapító rendszeres, havonta legalább 10 napon történő szedése kiválthatja, ezért minden olyan esetben gondolni kell rá, amikor koráb-ban is panaszos betegek fejfájásának gyakorisága -nagyobb mennyiségben szedett fájdalomcsillapítók mellett -megnő. A kórkép leggyakrabban a 40-50 éves nőket érinti: kockázatát növeli a dohányzás, az elhízás, a depresszió, valamint a szorongásos zavar. Kialakulásában biológiai (genetikai megalapozottság, neurokémiai és neurofi ziológiai eltérések) mellett pszichológiai, illetve életvezetési tényezők, így a fejfájásokra vonatkozó anticipátoros szorongás, a fájdalom katasztrofi zálása, az ezek miatti kényszeres gyógyszerszedő magatartás is fontos szerepet játszanak. A fáj-dalomcsillapító-túlhasználathoz társuló fejfájás kezelésének elengedhetetlen része a kiváltó szer megvonása, a megvonási tünetek (köztük a rebound fejfájás) kezelése, a hatásos preventív terápia bevezetése, a komorbid betegségek kezelése, valamint a betegek megfelelő oktatása és pszichés támogatása. Mivel a visszaesés esélye megfelelő kezelés mellett is 30-40% lehet, alapvető fontosságú a megelőzés, amelyben az alapellátás szerepét nem lehet eléggé hangsúlyozni. Orv. Hetil., 2015, 156(30), 1195-1202. Kulcsszavak: fejfájás, fájdalomcsillapító-túlhasználat Medication-overuse headacheMedication-overuse headache affects 1 to 2 percent of the population. Any kind of painkiller, if taken regularly at least 10 days per month can cause medication-overuse headache, and therefore the possibility of this headache has to be raised whenever a patient with a preexistent headache notices a signifi cant increase in headache frequency during a period of frequent painkiller consumption. Medication-overuse headache is most prevalent in females between 40 and 50 years of age. Its main risk factors are smokig, obesity, depression, and anxiety. The pathomechanism of medication-overuse headache is complex, with a probable genetic propensity and other biological (neurochemical and neurophysiological), as well as psychological and behavioural factors (such as anticipatory anxiety, catastrophisation of pain and consequentially a compulsive painkiller use) contributing to its genesis. The prerequisite of successful treatment is the withdrawal of the overused substance, other necessary elements of the therapy include the treatment of withdrawal symptoms including rebound headache, the introduction of an effective preventative therapy, taking into consideration the highly prevalent comorbid disorders as well, and the education and psychological support of patients. As the relapse rate can be as high as 30 to 40% regardless of effective treatment, the prevention of medication-overuse headache is of paramount importance, and the role of general practitioners can hardly be overstated.

show abstract

“…Chronic migraine associated to medication overuse (CM-MO) is an unfavourable outcome of migraine course, which seems to be mediated by lifestyle, life events, comorbid conditions, genetic terrain and medication overuse [1,2], and which determines a relevant burden, in particular in terms of increased disease cost [3]. A recent review showed that patients with a chronic form of headache report a remarkable impact on functioning, with high disability and reduction in work and non-work activities [4].…”

Section: Introductionmentioning

confidence: 99%

A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse

Raggi¹,

Leonardi²,

Giovannetti³

et al. 2013

Neurol Sci

View full text Add to dashboard Cite

This paper aims to evaluate changes in disease severity, disability and mood state in patients with chronic migraine associated to medication overuse (CM-MO). MIDAS was used for assessing disease activity, WHO-DAS-2 for disability, DBI-2 for mood state. ANOVA was used to test change over time; t-test to assess follow-up differences in WHO-DAS-2 and BDI-2 between patients with MIDAS B20 and C21. Change in MIDAS, WHO-DAS-2 and BDI-2 scores were computed: Pearson's index was used to assess correlation between them; linear regression to assess change in WHO-DAS-2, using MIDAS and BDI-2 change as predictors. Mean MIDAS decreased significantly (from 101.9 to 52.0). In 26

show abstract

The cost of headache disorders in Europe: the Eurolight project

Abstract: Headache disorders are prominent health-related drivers of immense economic losses for the EU. This has immediate implications for healthcare policy. Health care for headache can be both improved and cost saving.

Cited by 605 publications

References 26 publications

Migraine in Women: What Specificities? A Review

Migraine in Women: What Specificities? A Review

Fájdalomcsillapító-túlhasználathoz társuló fejfájás

A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse

Contact Info

Product

Resources

About